In the present study, we evaluated the anticancer activities of sitagliptin as a target for CD24/CTNNB1/SOX4, which were previously demonstrated to promote CRC progression, stemness, and metastasis [36,37,38]. This evidence concerns the gene CD24 and colorectal carcinoma.